Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

Ideaya Biosciences (IDYA) announced the selection of IDE034, a B7H3/PTK7 topo-I-payload BsADC, as a development candidate and the exercise of ...

Biocytogen announced that Ideaya Biosciences (IDYA) has exercised the option for an exclusive worldwide license for Biocytogen’s ...

Unicycive, which is seeking an FDA green light for oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis, Monday said the agency set a target ...

Dizal has submitted sunvozertinib’s new drug application (NDA) to the US Food and Drug Administration (FDA) aiming to secure approval for treating locally advanced or metastatic non-small cell lung ...

A study on mice investigating therapeutic food for malnourished children uncovers diverse functions of a newly identified gut ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

US endocrinologists are favoring antithyroid drugs over radioactive iodine in initial Graves’ disease treatment, and new ...

In an exciting development for drug development and patient care, the FDA has officially accepted the first submission of an organ-on-a-chip technology under its Innovative Science and Technology ...

MacroGenics (NASDAQ: MGNX) Q3 2024 Earnings Call Nov 05, 2024, 4:30 p.m. ET ...

In a tough fundraising space, cell therapy biotechs pursuing autoimmune indications review staffing to ensure the right ...

Out-of-pocket costs for branded drugs to treat multiple sclerosis (MS), Alzheimer's, and Parkinson's disease rose from 2012 ...